Amanda Fishback Cashen, M.D.

Peer-reviewed Manuscripts

• Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
  Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
  Am J Hematol 2009 Sep 11; [Epub ahead of print]
• Cashen AF
  Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.
  Drugs Today (Barc) 2009 Jul;45(7):497-505
• Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
  A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
  Am J Hematol 2009 Sep;84(9):560-4
• Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
  Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
  Bone Marrow Transplant 2009 Jul;44(1):13-7
• Cashen AF, Rubin DC, Bartlett NL
  Protein losing enteropathy associated with follicular lymphoma of the small bowel.
  Am J Clin Oncol 2009 Apr;32(2):222-3
• Uy GL, Rettig MP, Cashen AF
  Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
  Expert Opin Biol Ther 2008 Nov;8(11):1797-804
• Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J
  A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
  Biol Blood Marrow Transplant 2008 Nov;14(11):1253-61
• Cashen AF, Bartlett NL
  Salvage regimens for Hodgkin lymphoma.
  Clin Adv Hematol Oncol 2008 Jul;6(7):517-24
• Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
  Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
  Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
• Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J
  Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  Cancer Chemother Pharmacol 2008 Apr;61(5):759-66
• Cashen AF, Lazarus HM, Devine SM
  Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
  Bone Marrow Transplant 2007 May;39(10):577-88
• Gopalan PK, Clohisy JC, Cashen AF, Eby CS
  Use of recombinant factor VIIa for hip surgery in a patient with factor-VII deficiency. A case report.
  J Bone Joint Surg Am 2007 Feb;89(2):389-91
• Cashen AF, Nervi B, DiPersio J
  AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
  Future Oncol 2007 Feb;3(1):19-27
• Cashen AF, Bartlett NL
  Therapy of relapsed Hodgkin lymphoma.
  Blood Rev 2007 Sep;21(5):233-43
• Cashen AF, Devine H, Dipersio J
  Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
  Am J Hematol 2006 Jul;81(7):543-5
• Cashen AF, Schiller GJ, Larsen JS, Cullen MT, DiPersio JF
  Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML).
  Blood (ASH Annual Meeting Abstracts), 2006;108:1984
• Cashen AF, Link D, Devine S, DiPersio J
  Cytokines and stem cell mobilization for autologous and allogeneic transplantation.
  Curr Hematol Rep 2004 Nov;3(6):406-12
• Cashen A, DiPersio JF, Khoury H
  Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
  J Clin Oncol 2003 Nov 15;21(22):4255-6
• Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A
  Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.
  Oncogene 1999 Aug 5;18(31):4450-9
• Gutmann DH, Giordano MJ, Fishback AS, Guha A
  Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas.
  Neurology 1997 Jul;49(1):267-70
• Fishback AS, Shields CB, Linden RD, Zhang YP, Burke D
  The effects of propofol on rat transcranial magnetic motor evoked potentials.
  Neurosurgery 1995 Nov;37(5):969-74